AMS vs NVCR vs NKTR vs ARAY

For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.

9% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, American Shared Hospital Services (AMS) delivered a total return of -41.

1%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.

02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, American Shared Hospital Services (AMS) carries a lower debt/equity ratio of 77% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.

9% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, AMS leads at 17. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

American Shared Hospital Services (AMS) is the more profitable company, earning 7.

7% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARAY leads at 1. 7% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.